FDA-approved, but no longer sold in the US.
No perspectives yet — be the first!
Be the first verified clinician to share a view on Peginesatide.
100% anonymous · NPI-verifiedFDA status last checked Nov 11, 2026
A synthetic, non-recombinant, pegylated, peptidic erythropoiesis stimulating agent. Synthetic peptide-based erythropoiesis stimulating agent binds to and activates the erythropoietin (EPO) receptor on erythroid progenitor cells, thereby inducing their proliferation and differentiation into mature erythrocytes.
Peginesatide
Approved by the FDA, but no longer sold in the US.
Tested in at least one proper controlled study in people, with results.
No brand records are linked yet.
How it works. Proven facts and ideas still being studied are kept apart.
Not yet reviewed.
Tested in at least one proper controlled study in people, with results.
FDA-approved, but no longer sold in the US (all US products discontinued). Applications: NDA202799.
Last verified: Nov 11, 2026
Share your perspective on Peginesatide and help peers make informed prescribing decisions.
Your 45-second perspective helps thousands of colleagues.
Your real-world insights guide colleagues
Your identity stays private — only specialty/region shown
Compare your perspective to specialty peers
